ArticleThe Canadian journal of urology2026
Clinical and racial predictors of adverse pathology at radical prostatectomy: implications for undertreatment among patients receiving radiation and hormonal therapy.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUnder-grading exists in up to 7% of patients undergoing radical prostatectomy (RP) for prostate cancer (PC). We assessed whether underrepresented race and ethnicity disproportionately increased the odds of adverse pathology at RP in patients with biopsy Gleason score 6 or 7 PC at high-risk for upgrading and/or upstaging at RP based on age and PC indices at presentation.
methodsThis retrospective cohort study analyzed 76,474 patients in the National Cancer Database (2015-2021) with biopsy Gleason score 6 or 7 N0M0 PC. Odds ratio (OR) at RP of adverse pathology defined as prostatectomy (p) Gleason score 9-10, node-positive disease, or pT3b-T4 PC in patients at high- or highest-risk for upgrading at RP. The highest-risk group comprised age > 70 years, PSA > 10 ng/mL, cT2 or higher, ≥50% positive biopsy cores, and Black or other non-White race and/or Hispanic ethnicity versus the same clinical factors and White race and non-Hispanic ethnicity for high-risk. Others were classified as low-risk.
resultsThe adverse pathology OR was 4.36 (95% CI, 3.10-6.89), and 2.64 (95% CI, 2.25-3.08) for patients in the high-risk and highest-risk groups respectively compared to low-risk. Highest-risk patients had a significantly higher adverse pathology OR [1.70 (95% CI, 1.11-2.60); p = 0.015] when compared to high-risk patients.
conclusionsDisproportionate under-grading and under-staging observed in under-represented minorities can lead to under-treatment in the highest-risk patients electing to undergo radiation and androgen deprivation therapy (ADT), given ADT duration could be based on under-graded PC, highlighting the urgent need to improve the detection strategy in these patients.
Indexed as
Identifiers
42415579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.